DUBLIN--(BUSINESS WIRE)--Sep. 20, 2012--
Elan Corporation, plc (NYSE:ELN) today announced the appointment of Hans
Peter Hasler as Chief Operating Officer (“COO”) of the Company with
effect from October 1, 2012. Mr. Hasler is currently a non-executive
director of the Company and on his appointment as COO, he will retire
from the board of directors of the Company. Mr. Hasler was appointed a
director of Elan in September 2011. He is currently the chairman of HBM
Bioventures AG and principal of HPH Management GmbH. Mr. Hasler served
with Biogen Idec in a number of key executive leadership roles from 2001
to 2009, most recently as its COO responsible for all commercial
operations, business development, medical affairs and Biogen
International.
Elan’s Chairman, Robert Ingram, and CEO, Kelly Martin, commented “Hans
Peter has made a significant contribution to our company as a
non-executive board member over the last twelve months and will be a
valuable addition to our executive team. With over 20 years of
experience in the industry we are confident that as COO, Hans Peter will
be instrumental in helping position Elan for long-term growth in the
future. Elan will benefit from his wealth of experience and strong
leadership skills and we look forward to working with him as our COO.
Hans Peter will work closely with us and the board of directors on all
strategic and operational aspects of the company”.
About Elan
Elan is a neuroscience focused biotechnology company committed to making
a difference in the lives of patients and their families by dedicating
itself to bringing innovations in science to fill significant unmet
medical needs that continue to exist around the world. For additional
information about Elan, please visit http://www.elan.com.
Source: Elan Corporation
Investor Relations:
Chris Burns
Ph: 800-252-3526
David
Marshall
Ph:+ 353-1-709-4444
or
Media Relations
Emer
Reynolds
Ph: + 353-1-709-4022
Jonathan Birt
Ph:
+44-751-559-7858
RSS Feeds | 
E-mail Alerts | 
Contact IR